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Carotid Endarterectomy or Carotid Artery Stent Placement
Khan A, Adil MM, Qureshi AI, et al. Stroke 2014;45:595-7.
Conclusions: Non-ST-elevation myocardial infarction (NSTEMI) is
not a benign event after carotid endarterectomy (CEA) or carotid artery
stent (CAS) placement.
Summary: Most postoperative myocardial infarctions are NSTEMIs.
The rates of periprocedural NSTEMI are not routinely measured after
CEA or CAS. In this paper, the authors sought to evaluate the frequency
of NSTEMI after CEA or CAS in overall clinical practice and determine re-
lationships with in-hospital outcomes. NSTEMI frequency was determined
using the Nationwide Inpatient Survey from 2002 to 2009. In-hospital out-
comes assessed included mortality and composite of stroke, cardiac events,
and mortality data. Of 1,083,688 patients who underwent CEA or CAS,
11,341 (1%) had documented NSTEMI during their hospitalization. With
adjustment for constitutional variables and risk factors, NSTEMI was asso-
ciated with higher rates of in-hospital mortality (odds ratio, 8.6; 95% conﬁ-
dence interval, 7.0-10.7; P # .001) and higher rates of the composite end
point of stroke, cardiac events, and death (odds ratio, 14.6; 95% conﬁdence
interval, 13.0-16.5; P # .0001).
Comment: The ﬁndings demonstrate perioperative NSTEMI after
CEA or CAS is infrequent. In fact, the rate seems lower than expected, likely
reﬂecting the limitations of the database used for the study. However, it
does appear that patients with NSTEMI after CEA or CAS may be more
likely to have in-hospital adverse outcomes and therefore a signiﬁcantly
increased burden of health care resource use. These data do not indicate
NSTEMI was the cause of the adverse outcomes after CEA or CAS but
do suggest that it is a mark of more overall postoperative morbidity severity
after CEA or CAS.
Observations from the IMPROVE trial concerning the clinical care of
patients with ruptured abdominal aortic aneurysm
IMPROVE trial investigators. Br J Surg 2014;101:216-24.
Conclusions: Outcomes for repair of ruptured abdominal aortic an-
eurysms (rAAAs) might be improved by wider use of local anesthesia for
endovascular aneurysm repair (EVAR) and by recognizing that a minimum
blood pressure of 70 mm Hg may be too low a threshold for permissive
hypotension.
Summary: Most data on outcomes of patients with rAAAs come from
single-center studies and, as such, may be too small to identify clinical factors
that could improve overall patient outcomes. The IMPROVE study, a prag-
matic multicenter randomized clinical trial, allocated eligible patients with a
clinical diagnosis of rAAA to a strategy of endovascular repair of rAAA
(EVAR) or to open repair. IMPROVE showed no difference in 30-day mor-
tality with a strategy incorporating EVAR for rAAA repair compared with a
strategy of open repair for rAAA (IMPROVE trial investigators, Br Med J
2014;348:f7661). In this paper, the IMPROVE investigators sought to
analyze inﬂuences of time and manner of hospital presentation, ﬂuid volume
status, type of anesthesia, type of EVAR, and time to aneurysm repair on 30-
day mortality for rAAA. This was a prespeciﬁed plan of analyses to include
only the patients who underwent aneurysm repair for a proven diagnosis of
rAAA. Adjustments were made for potential confounding factors. In
IMPROVE, 568 of 613 randomized patients had a symptomatic or rAAA,
and diagnostic accuracy was 91%. Patients randomized outside routine work-
ing hours had higher operative mortality (adjusted odds ratio, 1.47; 95% con-
ﬁdence interval, 1.00-2.17). There was no difference in mortality rates
between those patients admitted directly to a trial center vs those transferred
to a trial center from a referring institution. Lowest systolic blood pressure
was strongly and independently associated with 30-day mortality (51% among
those with systolic blood pressures <70 mm Hg). In addition, patients who
received EVAR under local anesthesia alone had reduced 30-day mortality
compared with those who had EVAR under general anesthesia (adjusted
odds ratio, 0.27; 95% conﬁdence interval, 0.10-0.70). In patients with
conﬁrmed rupture, the time from randomization to the operating suite was
not associated with 30-day mortality (P ¼ .415).
Comment: The data indicate that a blood pressure of 70 mm Hg may
be too low for optimal results in a patient with rAAA and that permissivehypotensive levels should be above this. In addition, when EVAR is used
to treat a rAAA, it may be best to do it, if possible, under local anesthesia.
Finally, the fact that results for repair of rAAA are no worse for a patient who
is transferred than for those with a primary presentation to a specialist cen-
ter, along with the fact that patients undergoing off-hours repair do more
poorly, suggests a skilled multidisciplinary vascular team, including specialist
anesthesia services, is likely to provide the best results for repair of a rAAA in
any individual region. Outcomes for patients with rAAA therefore may be
best served by a policy of regionalization of care for such patients to special-
ized centers.
Early graft failure after infrainguinal arterial bypass
Soma G, Greenblatt DY, Nelson MT, et al. Surgery 2014;155:300-10.
Conclusions: Early graft failure (EGF) after infrainguinal arterial
bypass occurs in w5% of patients and is strongly associated with additional
complications and mortality.
Summary: Operative revascularization remains an important manage-
ment tool in the care of patients with advanced claudication or critical limb
ischemia. Most studies previously investigating EGF after infrainguinal
bypass have been single-institution studies. The authors point out that
two previous studies of this complication using a multi-institutional database
were derived from an era before endovascular intervention had become as
prevalent as is now (Singh N et al, J Vasc Surg 2008;47:556-61; and Conte
MS et al, J Vasc Surg 2006;43:742-51). In this study, the authors used data
from the American College of Surgeons National Surgical Quality Improve-
ment Program to determine the frequency of 30-day EGF after infrainguinal
arterial bypass. Univariate and multivariate analyses were then used to eval-
uate risk factors of EGF and additional complications associated in patients
with EGF. Of 23,468 patients who underwent infrainguinal arterial bypass,
1065 (4.5%) had EGF. Patients who had EGF were more likely to have a
prolonged duration of stay (34.8% vs 12.0%, P < .001), greater rates of
reoperation (82.1% vs 14.3%, P < .001), and increased 30-day mortality
(5.1% vs 2.1%, P < .001). The rate of additional complications in patients
who experienced EGF was 42% compared with 25.4% in those who did
not have EGF (P < .001). EGF in multivariate analyses was associated
with younger age, female sex, black race, obesity, thrombocytosis, increased
international normalized ratio, femoral-to-tibial bypass, prosthetic grafts,
and emergency operation. Patients who experience complications in addi-
tion to EGF were more likely to have complications after graft failure
(69.5% vs 31.3%).
Comment: The authors found an association between EGF and addi-
tional postoperative complications and overall mortality. The study perhaps
helps identify preoperatively patients at higher risk of EGF who may beneﬁt
from targeted interventions, such as postoperative anticoagulation, to
improve outcomes.
Cost-effectiveness and cost-utility of endovascular versus open repair of
ruptured abdominal aortic aneurysm in the Amsterdam Acute
Aneurysm Trial
Kapma MR, Dijksman LM, Reimerink JJ, et al. Br J Surg 2014;101:208-15.
Conclusions: In treatment of ruptured abdominal aortic aneurysm
(rAAA), the increased costs for endovascular aneurysm repair (EVAR)
means that it is unaffordable based on current standards of societal willing-
ness-to-pay for health gains.
Summary: In recent years, there has been increased interest in the use
of endovascular techniques for treatment of rAAA. Individual case series
have suggested improved mortality with EVAR for treatment of rAAA
compared with open treatment for rAAA. Two prospective trials, however,
have concluded there is no difference in the efﬁcacy of treatment. Additional
possible drawbacks of EVAR are the high costs of the stent grafts and
decreased applicability owing to anatomic insuitability of the AAA. The
Amsterdam Acute Aneurysm trial was a multicenter trial in Amsterdam
comparing open repair with EVAR in patients with rAAA (Reimerink JJ
et al, Ann Surg 2013;258:248-56). This trial took place in two university
academic medical centers and demonstrated equivalency of the end points
of rates of death and severe complication in the patients treated with1747
